Day: March 17, 2021

SACRAMENTO, Calif., March 17, 2021 (GLOBE NEWSWIRE) — Bank of Commerce Holdings (NASDAQ: BOCH) (the “Company”), a $1.764 billion asset bank holding company and parent company of Merchants Bank of Commerce (the “Bank”), today announced that the Board of Directors has authorized a cash dividend of $0.06 per share for the 2021 first quarter.The $0.06 per share quarterly cash dividend will be paid to shareholders of record as of March 30, 2021 and is payable on April 9, 2021.About Bank of Commerce HoldingsBank of Commerce Holdings is a bank holding company headquartered in Sacramento, California and is the parent company for Merchants Bank of Commerce. The Bank is an FDIC-insured California banking corporation providing community banking and financial services in northern California along the Interstate 5 corridor from Sacramento to...

TORONTO, March 17, 2021 (GLOBE NEWSWIRE) — Altus Group Limited (“Altus Group” or “the Company”) (TSX: AIF), a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry, announced today that the Board of Directors has approved the payment of a cash dividend of $0.15 per common share for the first quarter ending March 31, 2021.Payment will be made on April 15, 2021 to common shareholders of record as at March 31, 2021.Altus Group’s Dividend Reinvestment Plan (“DRIP”) permits eligible shareholders to direct their cash dividends to be reinvested in additional common shares of the Company. For shareholders who wish to reinvest their dividends under the DRIP, Altus Group intends to issue common shares from treasury at a price equal to 96% of the weighted average closing...

MCLEAN, Va., March 17, 2021 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) recently priced a new offering of Structured Pass-Through Certificates (K Certificates), which are backed by underlying collateral consisting of fixed-rate multifamily mortgages with predominantly 10-year terms. The company expects to issue approximately $1.4 billion in K Certificates (K-127 Certificates), which are expected to settle on or about March 25, 2021.K-127 PricingDetailsCo-Lead Managers and Joint Bookrunners: Wells Fargo Securities, LLC and Deutsche Bank Securities Inc.Co-Managers: J.P. Morgan Securities LLC, Loop Capital Markets LLC, Morgan Stanley & Co. LLC and Piper Sandler & Co.Rating Agencies: Fitch Ratings, Inc. and DBRS, Inc.Related LinksThe K-127 Preliminary Offering Circular Supplement: http://www.freddiemac.com/mbs/data/k127oc.pdf...

WALL, N.J., March 17, 2021 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity access management (IAM) and large scale identity solutions, including industry leading biometric capabilities, will host a conference call to review its fourth quarter and full FY 2020 results on Thursday, March 25, 2021 at 10 a.m. ET. Results will be reported prior to the market’s opening. Mike DePasquale, Chairman & CEO, Cecilia Welch, Chief Financial Officer, and Fred Corsentino, Chief Revenue Officer, will participate on the call.

Elfordonstillverkaren Clean Motion AB presenterar sin boksluts-kommuniké för 2020. Bolaget redovisar en försäljning på 1 517 TSEK (2 286 TSEK) och ett rörelseresultat på 11 112 TSEK (-12 961 TSEK). Den genomförda företagsrekonstruktionen gör att årsvisa jämförelser inte är meningsfulla. Ackordsvinsten blev 15 216 TSEK.Under perioden april-oktober befann sig företaget i rekonstruktion vilket gör jämförelser mellan 2019 och 2020 svåra. Resultatet av rekonstruktionen är ändå mycket positivt och visar en betydligt starkare balansräkning med 75% (32%) soliditet.Göran Folkesson VD-ord kommenterar finansiering, den pågående strukturomvandlingen, marknaden samt målsättningen med en ny produkt fokuserad på godstransporter.VD:ordet; ” 2020 går givetvis till historien som ett utmanande år. Men också som en nystart för verksamheten. Rekonstruktion...

Advancing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies – with Novel MoAs Beyond anti-VEGFRecruiting Phase 2 study (‘KALAHARI’) evaluating THR-149, a potent plasma kallikrein inhibitor in DME – On track for Part A data by mid-yearPositive data from Phase 1 study evaluating THR-687, potential best in class pan-RGD integrin antagonist in DME – On track to start Phase 2 by mid-yearHighlights              Industry-leading pipeline targeting a total potential market opportunity of $12 billion in retinal vascular disorders First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive...

Bankens repræsentantskab og bestyrelse har i forlængelse af dagens ordinære generalforsamling konstitueret sig som anført i vedlagte meddelelse.Vedhæftet filMeddelelse_nr5_2021